| Title | Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Pierrot, N, Lhommel, R, Quenon, L, Hanseeuw, B, Dricot, L, Sindic, C, Maloteaux, J-M, Octavea, J-N, Ivanoiu, A |
| Journal | J Alzheimers Dis |
| Volume | 49 |
| Issue | 2 |
| Pagination | 271-6 |
| Date Published | 2016 |
| ISSN | 1875-8908 |
| Keywords | Aged, Alzheimer Disease, Amyloidogenic Proteins, Biomarkers, Cognition Disorders, Humans, Male, Mental Recall, Neuropsychological Tests, Receptors, Retinoic Acid, tau Proteins, Tetrahydronaphthalenes |
| Abstract | We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD. |
| DOI | 10.3233/JAD-150405 |
| Alternate Journal | J. Alzheimers Dis. |
| PubMed ID | 26444777 |
